Merck (MRK) Q3 2026 (Media) earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 (Media) earnings summary
12 Nov, 2026Executive summary
Q3 net sales rose 5.1% organically to €5.627bn; growth was led by Life Science and Electronics, including Process Solutions, Rare Diseases and Semiconductor Solutions.
FY26 guidance was raised, reflecting stronger underlying performance and more favorable FX effects.
Financial highlights
Reported net sales increased 5.8% YoY to €5.627bn; organic growth was 5.1%, with a 1.5% FX benefit and a 0.8% portfolio drag.
EBITDA pre was €1.682bn, up 0.8% reported and 0.4% organically; prior-year EBITDA pre included one-time benefits.
Reported EBIT fell 46.5% to €653m and profit after tax fell 49.9% to €450m; EPS was €1.04 versus €2.07 YoY.
EPS pre was unchanged at €2.32; operating cash flow rose 9.4% to €1.660bn.
Net financial debt was €7.733bn at September 30, down 10.3% since year-end 2025; net financial debt to EBITDA pre was 1.2x.
Outlook and guidance
FY26 net sales guidance: €21.5–21.9bn, with organic growth of 3%–4% and FX impact of -1% to 0%.
FY26 EBITDA pre guidance: €6.2–6.4bn, with organic growth of 3%–5% and FX impact of -2% to 0%; EPS pre is €8.30–8.70.
FY26 free cash flow is expected at €2.3–2.7bn; guidance assumes a 22% underlying tax rate, Bio-Techne contribution for December, and no U.S. Mavenclad sales from November.
Life Science FY26 guidance: sales €9.4–9.6bn and EBITDA pre €2.75–2.85bn; organic growth of 6%–7% and 6%–8%, respectively.
Healthcare guidance: sales €8.5–8.7bn and EBITDA pre €2.9–3.0bn; Electronics guidance: sales ~€3.6bn and EBITDA pre ~€1.1bn.
Latest events from Merck
- A €0.9bn proposal adds a promising siRNA asset for rare blood cancer.MRK
Acquisition presentation - Raised FY26 guidance amid Q3 growth, CDMO impairment and Mavenclad pressure.MRK
Q3 2026 - Growth fueled by innovation, strategic M&A, and sustainability across all business sectors.MRK
Corporate presentation - Upgraded 2026 guidance as Life Science and Electronics drive growth, with margin expansion.MRK
Q2 2026 - Strong early oncology pipeline progress with promising DDR and ADC assets advancing to clinic.MRK
Investor Update - Q3 2025 delivered robust organic growth, higher margins, and a positive outlook despite FX risks.MRK
Q3 2025 - Growth and margin expansion driven by rare diseases, semiconductor solutions, and innovation.MRK
CMD 2025 - Growth, innovation, and sustainability drive upgraded ambitions and operational excellence.MRK
CMD 2024 - Q1 2025 delivered solid growth and margin gains, with guidance reflecting macro headwinds.MRK
Q1 2025